Table 1.

Efficacy and safety end points of the CREDENCE study that are included in this study

Primary end point	Composite of kidney failure, a doubling of serum creatinine from baseline, or death due to kidney or cardiovascular disease
Secondary kidney end points	Composite of kidney failure, a doubling of serum creatinine, or kidney death
	Composite of kidney failure or kidney death
	Composite of KRT initiation (dialysis for ≥30 days or kidney transplantation) or kidney death
	Kidney failure
	Doubling of serum creatinine
	Composite of kidney failure, or kidney or cardiovascular death
Secondary cardiovascular end points	Composite of cardiovascular death or hospitalization for heart failure
	Major adverse cardiovascular events composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
	Hospitalization for heart failure
	Cardiovascular death
	Death from any cause
	Composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure or unstable angina
Intermediate outcomes	Change in urine albumin-to-creatinine ratio
	Acute, chronic, and total eGFR slope
	Change in glycated hemoglobin
	Change in body weight
	Change in systolic BP
Safety outcomes
Kidney-related safety outcomes	Composite of AKI, anuria, azotemia, blood creatinine increased, blood urea increased, eGFR decreased, nephropathy toxic, renal failure, and renal impairment
	AKI
Other safety outcomes	Volume depletion
	Hyperkalemia
	Urinary tract infections
	Hypoglycemia

Table adapted from efficacy and end points of Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE).